Publication: Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NFκB signaling pathway in the mouse hippocampus
Issued Date
2021-12-20
Resource Type
ISSN
18784216
02785846
02785846
Other identifier(s)
2-s2.0-85091246324
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Progress in Neuro-Psychopharmacology and Biological Psychiatry. Vol.111, (2021)
Suggested Citation
Thit Lwin, Jenq Lin Yang, Sukonthar Ngampramuan, Kittikun Viwatpinyo, Pongrung Chancharoen, Nisarath Veschsanit, Jitrapa Pinyomahakul, Piyarat Govitrapong, Sujira Mukda Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NFκB signaling pathway in the mouse hippocampus. Progress in Neuro-Psychopharmacology and Biological Psychiatry. Vol.111, (2021). doi:10.1016/j.pnpbp.2020.110109 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/78892
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Melatonin ameliorates methamphetamine-induced cognitive impairments by inhibiting neuroinflammation via suppression of the TLR4/MyD88/NFκB signaling pathway in the mouse hippocampus
Abstract
Methamphetamine (METH) is a highly addictive psychostimulant that causes significant health issues due to high prevalence of its illegal use. Chronic use of METH is associated with cognitive impairments in both human and animal studies, but the underlying mechanism remains unclear. METH-induced neuroinflammation is, potentially, one of the factors that causes cognitive impairments. Therefore, the present study aimed to assess whether melatonin could provide protection against inflammation, in a manner comparable to the anti-inflammatory agent, minocycline, with consequent improvements of METH-induced cognitive impairments and associated abnormalities in the mouse hippocampus. Results from the Morris water maze (MWM) test and the novel object recognition test (NORT) showed that melatonin given after METH injections could ameliorate both METH-induced spatial and recognition memory impairments. These memory impairments are associated with changes in the neuroinflammatory profiles, including IL-6, IL-1β, and TNF-α, both in the blood serum and hippocampus of adult mice. METH-treated mice also exhibited reactive astrocytes and activated microglia in the hippocampus. METH-induced activation of glial cells is associated with the activation of the TLR4/MyD88/NFκB signaling pathway. Moreover, melatonin administration led to recovery of these METH-induced markers to control levels. Thus, we conclude that melatonin could potentially be used as a cognitive enhancer and anti-inflammatory agent in the treatment of METH use disorder in humans.